NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Recommendation of “Hold” by Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $36.75.

NRXP has been the topic of several analyst reports. Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, November 23rd. HC Wainwright reaffirmed a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NRXP. Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 50.3% during the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after buying an additional 1,018,853 shares during the last quarter. Vanguard Group Inc. lifted its position in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares in the last quarter. Commonwealth Equity Services LLC bought a new stake in NRx Pharmaceuticals during the fourth quarter worth $994,000. AdvisorShares Investments LLC boosted its holdings in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after acquiring an additional 78,339 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of NRx Pharmaceuticals by 17.8% in the 4th quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after acquiring an additional 33,004 shares in the last quarter. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Performance

Shares of NRXP stock opened at $1.84 on Friday. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84. The business’s 50-day moving average price is $2.18 and its 200-day moving average price is $2.55. The firm has a market capitalization of $58.64 million, a price-to-earnings ratio of -0.78 and a beta of 1.91.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.